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INTRODUCTION 1 
Chitosan (CS) is a natural polysaccharide, composed of -D-glucosamine (60% <) and -D-N-2 
acetylglucosamine linking through a -(1→4) linkage, obtained by chitin deacetylation.1 CS 3 
is one of the most commercially important biocompatible polymers from an environmental or 4 
biomedical viewpoint.
2
 Because of CS’s biocompatibility and the high reactivity of amino 5 
groups, considerable research efforts have been directed toward developing safe and efficient 6 
chitosan-based materials as biomaterials.
1-3
 7 
Cyclodextrin (CyD) is a host molecule that forms inclusion complexes with a variety of 8 
guests.
4
 It has thus been widely used as an excipient to improve the physicochemical and 9 
pharmaceutical properties of drug molecules.
 
The grafting of CyD onto CS can result in an 10 
increase in the extent of complexation ability, sorption, and controlled-release properties due 11 
to CyD’s inclusion properties.5 We previously reported interesting abilities of a -12 
CyD−grafted chitosan (-CyD-g-CS) that formed supramolecular aggregates with insulin6 and 13 
cholesterol
7
. Although CyD-g-CS is scientifically fascinating and potentially applicable as a 14 
biomaterial, its synthesis is not easy because multiple steps and cumbersome isolations are 15 
necessary to prepare a CyD derivative bearing one reactive group such as carboxylic acid or 16 
aldehyde.
5-8
 A facile method with shorter steps and an easier procedure would accelerate the 17 
further application and functionalization of CyD-g-CS. Besides, both CS 
9-12
 and CyD 18 
derivatives
13-15
 are known as candidate materials for anticancer drug delivery systems. 19 
Thereby, CyD-g-CSs, which are conjugates of both candidates, and their derivatives would 20 
provide improved anticancer drug delivery systems showing enhanced binding of a drug as 21 
well as improved therapeutic efficacy. 22 
Herein we investigated facile preparation of -, -, and -CyD-g-CSs by 23 
carboxymethylation of the CyDs without purification and a subsequent dehydration-24 
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condensation reaction to CS (Scheme 1). Furthermore, doxorubicin (Dox)-capturing 1 
nanoparticles composed of CyD-g-CS and sodium triphosphate (TPP) were prepared. 2 
 3 
EXPERIMENTAL PROCEDURES 4 
Materials 5 
Chitosan (CS) (Mn estimated by GPC analysis with pullulan standards was 64 kDa 6 
*(MW/Mn=2.0)). The degree of deacetylation as estimated by elemental analysis was 76.5%) 7 
was supplied by Koyo Chemical CO., Ltd. (Tottori, Japan). -, -, and -CyDs and sodium 8 
triphosphate (TPP) were purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Chloroacetic 9 
acid, 2-morpholinoethanesulfonic acid (MES), 1-ethyl-3-(3-10 
dimethylaminopropyl)carbodiimide hydrochloride (EDC), and N-hydroxysuccinimide (NHS) 11 
were purchased from Tokyo Chemical Industry CO., Ltd. (Tokyo, Japan). Other reagents 12 
were obtained in commercial grade and used without further purification. 13 
 14 
Measurements 15 
Nuclear magnetic resonance (NMR) spectra were acquired on a JNM-ECP500 (JEOL, Tokyo, 16 
Japan). Infrared (IR) spectra of the samples were recorded with a Spectrum 65 (Perkin-Elmer 17 
Japan Co., Ltd., Tokyo, Japan) equipped with an ATR attachment. MALDI–TOF mass 18 
spectra were measured using an Autoflex-T2 (Bruker Japan, Kanagawa, Japan) using 2,5-19 
dihydroxybenzoic acid as a matrix. To prepare matrix solution, 2,5-dihydroxybenzoic acid 20 
(1.0 mg) was dissolved in acetonitrile (50 L), to which 0.1% trifluoroacetic acid aqueous 21 
solution (50 L) was added. The matrix solution (0.5 L) and sample solution (0.5 L; 1 22 
mg/mL) were mixed and dried naturally on a sample plate to form a matrix crystal for the 23 
analysis. Elemental analysis data were recorded on a Perkin Elmer 2400 II CHNS/O (Perkin-24 
Elmer Japan Co., Ltd., Japan). Dynamic light scattering (DLS) was performed with an ELSZ-25 
1000 zeta potential and particle size analyzer (Otsuka Electronics Co., Ltd., Osaka, Japan). 26 
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 1 
Preparation of the CyD-g-CS 2 
Typically, -CyD (0.50 g, 0.44 mmol) and sodium hydroxide (0.47 g, 12 mmol) were added 3 
to water (5.0 mL) and stirred for 10 min at 50 
o
C. To which, 16.2% chloroacetic acid solution 4 
(0.26 g, 0.44 mmol) was added dropwise. After the solution was continuously stirred at 50 
o
C 5 
for 24 h, it was cooled to room temperature. The solution was then adjusted to pH 7 by adding 6 
1.0 M HCl aqueous solution. The solution was poured into a large volume of acetone. The 7 
crude product containing a carboxymethylated -CyD (CM--CyD) was collected by 8 
filtration, followed by drying under reduced pressure. The CM--CyD content in the crude 9 
product was estimated to be 0.088 mmol by 
1
H NMR analysis. CS (0.13 g, 0.88 mmol) and 10 
the crude product were dissolved in 0.1 M MES aqueous solution (10 mL), to which EDC (34 11 
mg, 0.18 mmol) and NHS (11 mg, 0.088 mmol) were added. The reaction mixture was stirred 12 
overnight at room temperature. After the addition of triethylamine (1 mL), the reaction 13 
mixture was poured into a large volume of ethanol. The precipitated product was collected by 14 
centrifugation, followed by washing with ethanol. The precipitate was purified by dialysis 15 
with a visking tube (Mw cutoff: 15 kDa) in a large volume of water. Yield, 17% (0.20 g). 
1
H 16 
NMR (500 MHz, CD3COOD-D2O, DSS, 70 
o
C)  = 3.13 (-CH(NH2)- (chitosan, H-2)), 3.21-17 
3.42 (sugar protons (CyD)), 3.48-3.94 (sugar protons (chitosan, CyD)), 3.97-4.12 (CyD), 4.55 18 
(-CH(OH)- (N-acetylglucosamine and CyD-bearing units, H-1)), 4.79 (CH(OH)- 19 
(glucosamine units, H-1)), 4.99 (-CH(OH)- (CyD, H-1)), 5.20 (-CH(OH)- (CyD CM-glucose 20 
unit, H-1)), 5.30 (-CH(OH)- (CyD CM-glucose unit, H-1)). 
13
C NMR (125 MHz, CD3COOD-21 
D2O, DSS).  = 22.17 (chitosan, -NHCOCH3), 55.76 (chitosan, C-2), 58.81 (chitosan, C-6), 22 
60.40 (CyD, C-6), 61.02 (CM-CyD, C-6’), 70.40 (chitosan, C-3), 70.62 (-CH2CONH-, CM-23 
CyD), 72.01 (CyD, C-2), 72.37 (CyD, C-3), 73.29 (CyD, C-5), 75.05 (chitosan, C-5), 78.50 24 
(chitosan, C-4), 81.33 (CyD, C-4), 97,79 (chitosan, C1), 102.01 (CyD, C-1), 174.14 (-25 
CH2CONH- (CM-CyD)), 174.41 (NHCOCH3 (chitosan)). IR（cm
-1
, neat）3371, 2923, 2894, 26 
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1647, 1548, 1416, 1381, 1313, 1246, 1153, 1061, 1024, 944, 896. Elemental analysis calcd. 1 
for (C6H11NO4)7.3(C8H13NO5)2.6(C50H81NO40)1.0･3.3H2O C 44.40 H 6.56 N 4.92, found 2 
C .44.56 H 6.48 N 4.75. 3 
 4 
Binding constants between CyD and Dox 5 
The binding constants (M
-1
) between the CyD or the CyD residue and Dox were estimated 6 
from 
1
H NMR measurements. A Benesi-Hildebrand−type equation16 was employed:  7 
  aCyDaK
111
0




      (1) 8 
where ,  0, K, and a are the chemical shift of a signal attributed to an aromatic proton of Dox 9 
in the presence and absence of CyD, the binding constant, and a constant, respectively. 10 
 11 
Preparation of Dox-capturing nanoparticles composed of CyD-g-CS and TPP 12 
Typically, -, -, or -CyD-g-CS (10 mg) or CS (5.9 mg) was dissolved in 100 mM 13 
CH3COOH aqueous solution (1.0 mL), to which 1.0 mM Dox aqueous solution (1.0 mL) was 14 
added. After the solution was stirred for 1 h, 1.0 mM TPP aqueous solution (100 L) was 15 
added and the solution was stirred again for 1 h. The solution containing the nanoparticle was 16 
placed in a centrifugation tube equipped with semi-permeable membranes whose molecular-17 
weight cutoff was 3 kDa (Amicon Ultra-0.5, Millipore, Darmstadt, Germany). The tube was 18 
centrifuged at 5000 rpm at 25.0 
o
C. Absorbance of the filtrate, which had passed through the 19 
membrane, at 480 nm was measured to determine Dox concentration by a standard curve. The 20 
adsorption of Dox to tubes and membranes was negligible, and the mass balance before and 21 
after membrane separation was maintained. Capturing efficiency (%) was defined as follows: 22 
   
 
100
0
0 


Dox
DoxDox
EfficiencyCapturing    (2) 23 
where [Dox] and [Dox0] are the Dox concertation of the filtrates in the presence and absence 24 
of the nanoparticle, respectively.  25 
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 1 
RESULTS AND DISCUSSION 2 
Preparation of CyD-g-CS 3 
Facile preparation of -CyD-g-CS by means of the carboxymethylation of -CyD and the 4 
dehydration-condensation reaction to CS was investigated. The carboxymethylation of -CyD 5 
was carried out with an equivalent amount of chloroacetic acid. The crude product containing 6 
CM--CyD and impurities (-CyD unreacted and NaCl) was obtained by precipitation with a 7 
large volume of ethanol. MALDI-TOF mass and 
1
H NMR analyses of the crude product were 8 
performed. Figure 1A shows the MALDI-TOF mass spectrum of the crude product. In the 9 
spectrum, significant peaks attributed to -CyD and CM--CyD were observed at 1157 Da 10 
(-CyD + Na+), 1216 Da (CM--CyD + Na+), and 1238 Da (CM--CyD-Na salt + Na+). 11 
Peaks attributable to a di-substituted product (CM2--CyD) were slightly observed at 1295 Da 12 
and 1318 Da, which were trace amounts compared to CM--CyD in HPLC analysis with an 13 
ODS column. Figure 1B shows the 
1
H NMR spectrum of the crude product. In the spectrum, 14 
signals attributable to the anomeric protons of the glucose units in -CyD and CM--CyD (b), 15 
the 6-O-carboxymethylglucose unit in CM--CyD (a), and the 2 and/or 3-O-16 
carboxymethylglucose unit in CM--CyD (a’) were observed at 5.12 ppm, 5.32 ppm, and 17 
5.43 ppm, respectively. The apparent yields estimated from the integrated ratio of the 18 
anomeric protons of carboxymethylglucose units (a and a’) and of glucose units (b) were 19 
19.8%. Subsequently, the crude product containing CM--CyD was conducted to the grafting 20 
reaction onto CS by the dehydration-condensation reaction without further purification, where 21 
the molar feed ratio (CM--CyD/CS unit) was adjusted to 0.10. Finally, the impurities from 22 
both carboxymethylation and the dehydration-condensation reaction were removed by dialysis. 23 
The structure of the -CyD-g-CS was confirmed by 1H NMR analysis (Figure 1C), revealing 24 
signals attributed to protons of residual acetyl groups in a CS (g), the 2-position of unreacted-25 
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glucosamine units in CS (f), a methylene in carboxymethyl moiety (e), most of the sugar 1 
protons in CS and CyD residues (sugar protons), anomeric protons of CS (d, c), and -CyD 2 
residues (a, a’, and b). In addition, 13C NMR, IR, and elemental analyses (see the 3 
experimental section) also supported the production of -CyD-g-CS. The -CyD content, 4 
which is the molar ratio of the CyD-bearing glucosamine unit in the -CyD-g-CS, was 5 
estimated from the integrated ratio of anomeric protons of CS (c and d) and the -CyD 6 
residues (a, a’, and b) to be 9.6%. This was nearly identical to the value estimated from 7 
elemental analysis (9.2%). This agreed well with the feed ratio. The total yield of -CyD-g-8 
CS in the two steps was 16.7%, which was about twice that of our previous route through five 9 
steps from -CyD.6 Besides, our previous route requires 2 weeks to prepare -CyD-g-CS, 10 
whereas the present method requires only 3 days. Furthermore, we demonstrated that the CyD 11 
content in -CyD-g-CS was controllable by varying the feed ratio (Table 1, Entries 1-3), and 12 
this method was applicable to the preparation of - and -CyD-g-CS (Table 1, Entries 4-6; 13 
Figure S1 and S2). Note that twice the amount of EDC was needed in the case of -CyD than 14 
in the case of - or -CyD. This is probably due to inhibition by -CyD, because -CyD can 15 
include EDC.
4
 16 
Although the condition of caroboxymethylation of CyD and the reaction system for 17 
the dehydration-condensation reaction differed from those for this study, there is a report 18 
concerning the preparation of -CyD-g-CS through the carboxymethylation of CyD.8 To 19 
compare that study to the method proposed here, we attempted to prepare -CyD-g-CS using 20 
those previously reported conditions. -CyD was carboxymethylated in accordance with the 21 
previous report, in which 5.3 equivalent of chloroacetic acid was used. Although the apparent 22 
yield estimated by 
1
H NMR analysis was higher (68.4%) than that in this study (Figure S3B), 23 
distinct peaks attributed to di- and tri-substituted products (CM2--CyD and CM3--CyD) are 24 
observed in the MALDI-TOF mass analysis (Figure S3A). In the dehydration-condensation 25 
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reaction with the crude product containing CM--CyD, CM2--CyD, and CM3--CyD by the 1 
EDC/NHS system used in this study, the reaction solution turned into a gel during the reaction 2 
due to a crosslinking reaction involving CM2--CyD and CM3--CyD. The purified product 3 
was an insoluble material. These results suggest that the reported method is applicable only to 4 
an oligomeric CS, as reported. 5 
 6 
Binding between Dox and the CyD residues 7 
Binding between Dox and the -, -, or -CyD residue via a host−guest interaction was 8 
investigated by 
1
H NMR analysis (Figure S4), where we used CyD-g-CSs having CyD 9 
contents of ca. 10% and an equivalent amount of Dox toward the CyD residue. In the case of 10 
-CyD-g-CS, the signals attributed to Dox were not changed at all. In the case of -CyD-g-11 
CS, the signal attributed to an aromatic proton of Dox was slightly shifted. In contrast, in the 12 
case of -CyD-g-CS some signals were significantly shifted. These results are consistent with 13 
the previously reported inclusion behavior of -, -, or-CyD toward Dox.14,17 The binding 14 
constant (K) due to the host−guest interactions between Dox and the - or -CyD residues was 15 
estimated from Benesi-Hildebrand plots (Figure 2 and S5). Linear relations, indicating the 16 
formation of inclusion complexes with 1:1 stoichiometry, were shown in both - and -CyD-17 
g-CS. The K values for the - and -CyD-g-CS estimated from the slopes and intercepts were 18 
6.2 M
-1
 and 171.5 M
-1
, respectively, which were almost the same as those for - and -CyD 19 
(7.2 M
-1
 and 225.1 M
-1
, respectively). These results indicate that the inclusion ability of the - 20 
or -CyD residue is not changed as much as that of - or -CyD. 21 
 22 
Preparation of Dox-capturing nanoparticles composed of CyD-g-CS and TPP 23 
TPP is a frequently used polyanionic crosslinker for the preparation of a CS nanoparticle. The 24 
nanoparticle is used as a drug carrier for Dox,
12
 where Dox is captured via the electrostatic 25 
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attraction of TPP. Inclusion by CyD residues would enhance adsorption via the host−guest 1 
interaction. Thus, we investigated the preparation of a Dox-capturing nanoparticle with -, -, 2 
or -CyD-g-CS and TPP. The -, -, and -CyD-g-CSs were converted into nanoparticles in 3 
the presence of Dox by the addition of TPP solution. The production of nanoparticles was 4 
confirmed by DLS and SEM analyses, in which nanoparticles ca. 100 nm in diameter and 5 
their aggregates (ca. 600 nm) were observed (Figure S6). Figure 3A shows the capturing 6 
efficiency of the nanoparticles for Dox estimated with a centrifugation tube equipped with 7 
semi-permeable membranes. The capturing efficiencies of the nanoparticles prepared with CS, 8 
-, -, and -CyD-g-CS were 17.0%, 17.1%, 20.2%, and 28.6%, respectively. In the case of -9 
CyD-g-CS forming a moderate inclusion complex with Dox, the capturing efficiency was ca. 10 
1.7-fold higher than that in CS. It is likely that the higher capturing efficiency is attributable 11 
to both the host−guest and electrostatic interactions (Figure 3B). In order to confirm the 12 
contribution of the inclusion, the capturing efficiency in the presence of large amount of 13 
poly(ethylene glycol), that is a macromolecuar guest for -CyD18, was evaluated, in which the 14 
capturing efficiency was decreased to 18.4%. This result indicates the inclusion by -CyD-g-15 
CS enhanced the capturing efficiency for Dox 16 
 17 
Conclusion 18 
We have developed a facile method of preparing CyD-g-CS by means of the 19 
carboxymethlation of CyDs and the dehydration-condensation reaction to CS. In this method, 20 
crude product containing ca. 10% of the CM-CyD was subjected to the grafting reaction 21 
without further purification. The product (CyD-g-CS) was finally purified by dialysis. This 22 
method was applicable to all common CyDs (- , - , and -CyD). Besides, the CyD content 23 
was changeable by the feed ratio (CM-CyD/CS unit). CyD-g-CS was obtained in higher yield 24 
in a shorter period of time compared to our previous report. This facile method makes further 25 
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functionalization of the CyD-g-CS accessible. We have found that the inclusion by -CyD-g-1 
CS enhanced the capturing efficiency for Dox. Further functionalization of CyD-g-CS for 2 
tumor targeting and a triggered release would provide an improved Dox delivery system. This 3 
work is now in progress. 4 
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 1 
Table 1 Preparation of -, -, and -CyD-g-CS in various feed ratios 2 
Entry CyD 
CM-CyDa/CS 
unit 
(mol/mol) 
EDC/CM-
CyD 
(mol/mol) 
CyD 
content 
(%)a,b 
Total 
Yieldc 
(%) 
1  0.20 2 18.2 15.3 
2  0.10 2 9.6 16.5 
3  0.05 2 4.1 16.3 
4  0.10 2 3.4 - 
5  0.10 4 11.4 15.3 
6  0.10 2 10.6 16.4 
a Estimated by 1H NMR analysis. b Molar ratio of CyD-bearing 3 
glucosamine unit in CyD-g-CS. c Estimated as follows: (Yield of 4 
CyD-g-CS (g)/Theoretical Yield (g) when CyD is perfectly 5 
converted to CyD-g-CS)x100. 6 
7 
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Scheme 1 1 
-,-,or -CyD-g-CS
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(Crude product)
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Scheme and Figure Captions 1 
 2 
Scheme 1 Facile preparation of -, -, or -CyD-g-CS. 3 
Figure 1 MALDI-TOF mass (A) and 
1
H NMR (B) spectra of crude CM--CyD and 1H NMR 4 
spectrum of -CyD-g-CS (C). 5 
Figure 2 Benesi-Hildebrand plots of the -CyD-Dox system (□), the -CyD-g-CS-Dox 6 
system (■), the -CyD-Dox system (△), and the -CyD-g-CS-Dox system (▲). 7 
Figure 3 Capturing efficiencies of the nanoparticles prepared with CS,-, -, or -CyD-g-CS 8 
for Dox (A) and a graphical image of the binding modes in the nanoparticle prepared with -9 
CyD-g-CS (B). 10 
 11 
Table Caption 12 
Table 1 Preparation of -, -, and -CyD-g-CS in various feed ratios 13 
